BioSig Technologies (OTCMKTS:BSGM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday, December 1st. The brokerage presently has a $1.50 price target on the stock. Zacks Investment Research‘s price target indicates a potential upside of 11.11% from the company’s current price.
According to Zacks, “BioSig Technologies, Inc. is a medical device company which is engaged in developing technology platform to improve cardiac recording during electrophysiology studies and ablation procedures. “
Separately, Chardan Capital reiterated a “buy” rating on shares of BioSig Technologies in a research note on Sunday, October 1st.
BioSig Technologies (OTCMKTS:BSGM) opened at $1.35 on Friday. BioSig Technologies has a twelve month low of $1.20 and a twelve month high of $2.00.
ILLEGAL ACTIVITY WARNING: “BioSig Technologies (BSGM) Raised to “Buy” at Zacks Investment Research” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/14/biosig-technologies-bsgm-upgraded-by-zacks-investment-research-to-buy.html.
BioSig Technologies Company Profile
BioSig Technologies, Inc is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System.
Get a free copy of the Zacks research report on BioSig Technologies (BSGM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.